Table 1 Demographic data and risk factors in the study groups
From: Hypoglycemia and hyperglycemia in extremely low-birth-weight infants
| Â | N-Group N=79 | Hypo-Group N=21 | Hyper-Group N=53 | Hypo&Hyper-Group N=13 |
|---|---|---|---|---|
GA (wks), mean±SD | 26.8±2.0 | 27.7±2.4 | 26.1±2.1 | 26.8±1.8 |
BW (g), mean±SD | 808±136 | 719±140 | 695±146 | 692±140 |
Male, n (%) | 17 (21.5) | 10 (47.6) | 26 (49.0) | 8 (61.5) |
SGA, n (%) | 22 (27.8) | 11 (52.3) | 16 (30.1) | 4 (30.7) |
Apgar1 <6, n (%) | 39 (49.3) | 9 (42.8) | 34 (64.1) | 8 (61.5) |
Apgar5 <6, n (%) | 8 (10.1) | 0 | 9 (16.9) | 2 (15.3) |
Intubation, n (%) | 47 (59.4) | 11 (52.3) | 37 (69.8) | 10 (76.9) |
Antenatal Steroid, n (%) | 64 (81.0) | 17 (80.9) | 41 (77.3) | 12 (92.3) |
RDS, n (%) | 66 (83.5) | 19 (90.4) | 49 (92.4) | 13 (100) |
Sepsis, n (%) | 16 (20.2) | 4 (19.0) | 32 (60.3) | 7 (53.8) |
Inotropic Agents, n (%) | 26 (32.9) | 6 (28.5) | 28 (52.8) | 8 (61.5) |
Xanthines, n (%) | 70 (88.6) | 20 (95.2) | 50 (94.3) | 13 (100) |
Postnatal Steroid, n (%) | 11 (13.9) | 3 (14.2) | 18 (33.9) | 3 (23.0) |
NEC, n (%) | 6 (7.5) | 2 (9.5) | 5 (9.4) | 4 (30.7) |
Medical treatment for PDA, n (%) | 34 (43.0) | 8 (38.0) | 34 (64.1) | 9 (69.2) |
Surgical Procedures, n (%) | 5 (6.3) | 3 (14.2) | 7 (13.2) | 2 (3.7) |